person · Reporting owner

Klencke Barbara

Disclosed activity across 5 companies

Tapewire entity: 31402
SEC CIK: 0001647647

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040	Chief Medical Officer	April 16, 2026	April 17, 2026
TScan Therapeutics, Inc.TCRX · Entity 7255	Director	May 20, 2026	May 22, 2026
Xencor IncXNCR · Entity 4487	Director	June 16, 2026	July 08, 2026
eFFECTOR Therapeutics, Inc.EFTR · Entity 89916	Director	June 13, 2024	June 13, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALX ONCOLOGY HOLDINGS INC

Report date April 16, 2026 · Filed April 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2036-04-15	Direct	100,000	Reported balance After 2026-04-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-16 · Grant · Acquired 100,000 · Balance 100,000 F1: One-fourth of the shares subject to the option vest on February 25, 2027 and 1/48th vest monthly thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: One-fourth of the shares subject to the option vest on February 25, 2027 and 1/48th vest monthly thereafter.

TScan Therapeutics, Inc.

Report date May 20, 2026 · Filed May 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2036-05-20	Direct	67,000	Reported balance After 2026-05-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-20 · Grant · Acquired 67,000 · Balance 67,000 F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.

Xencor Inc

Report date June 16, 2026 · Filed July 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	29,974	Reported balance After 2026-06-16 transaction · row 1 1 source row Row 1 · 2026-06-16 · Grant · Acquired 10,302 · Balance 29,974 F1: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.20 · Expires 2036-06-15	Direct	20,604	Reported balance After 2026-06-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-16 · Grant · Acquired 20,604 · Balance 20,604 F2: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant.

F2: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027.

eFFECTOR Therapeutics, Inc.

Report date June 13, 2024 · Filed June 13, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 · Expires 2034-06-12	Direct	800	Reported balance After 2024-06-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-13 · Grant · Acquired 800 · Balance 800 F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest in full on the earlier to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest in full on the earlier to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Sierra Oncology, Inc.

Report date July 01, 2022 · Filed July 01, 2022

Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-07-01 transaction · row 1 1 source row Row 1 · 2022-07-01 · Disposition to issuer · Disposed 10,000 · Balance 0
Common StockSEC Table I · non-derivative	IndirectBy spouse	Reported balance After 2022-07-01 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-07-01 · Disposition to issuer · Disposed 5,000 · Balance 0
Stock Option (right to buySEC Table II · derivative / convertible security · Conversion / exercise price $268.20 · Expires 2025-06-10	Direct	Reported balance After 2022-07-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-07-01 · Disposition to issuer · Disposed 11,744 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F1: The option fully vested on June 11, 2019.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $263.20 · Expires 2016-03-08	Direct	Reported balance After 2022-07-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-07-01 · Disposition to issuer · Disposed 2,061 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F3: The option fully vested on January 1, 2020.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.80 · Expires 2026-09-30	Direct	Reported balance After 2022-07-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-07-01 · Disposition to issuer · Disposed 11,399 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F4: The option fully vested on September 30, 2019.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.00 · Expires 2027-03-06	Direct	Reported balance After 2022-07-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-07-01 · Disposition to issuer · Disposed 1,749 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F5: The option fully vested on January 1, 2021.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.40 · Expires 2028-03-06	Direct	Reported balance After 2022-07-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-07-01 · Disposition to issuer · Disposed 4,508 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F6: The option fully vested on January 1, 2022.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.40 · Expires 2029-03-04	Direct	Reported balance After 2022-07-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-07-01 · Disposition to issuer · Disposed 4,999 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F7: The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.31 · Expires 2030-02-25	Direct	Reported balance After 2022-07-01 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-07-01 · Disposition to issuer · Disposed 167,091 · Balance 0 F9: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F8: The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.15 · Expires 2030-08-12	Direct	Reported balance After 2022-07-01 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-07-01 · Disposition to issuer · Disposed 49,000 · Balance 0 F9: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F10: On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.73 · Expires 2031-03-15	Direct	Reported balance After 2022-07-01 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-07-01 · Disposition to issuer · Disposed 30,000 · Balance 0 F9: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F11: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.54 · Expires 2032-03-14	Direct	Reported balance After 2022-07-01 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-07-01 · Disposition to issuer · Disposed 50,000 · Balance 0 F9: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F12: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option fully vested on June 11, 2019.

F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger.

F3: The option fully vested on January 1, 2020.

F4: The option fully vested on September 30, 2019.

F5: The option fully vested on January 1, 2021.

F6: The option fully vested on January 1, 2022.

F7: The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.

F8: The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F9: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.

F10: On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.

F11: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.

F12: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 16, 2026 Filed Jul 8, 2026 22:54 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	20,604	$0.00 Strike: $12.20	$0.00	Disclosure SEC source: 0001647647-26-000002 · wk-form4_1783551259.xml · derivative · entry 2 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,604 Underlying: Common Stock · 20,604 shares Expires 2036-06-15 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027. Read SEC document
June 16, 2026 Filed Jul 8, 2026 22:54 UTC	Xencor Inc XNCR · Entity 4487	GrantCommon Stock	10,302	$0.00	$0.00	Disclosure SEC source: 0001647647-26-000002 · wk-form4_1783551259.xml · nonDerivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,974 F1 · shares: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. Read SEC document
May 20, 2026 Filed May 22, 2026 20:05 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	GrantStock Option (Right to Buy) · Derivative	67,000	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001193125-26-236841 · ownership.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Voting Common Stock · 67,000 shares Expires 2036-05-20 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. Read SEC document
April 16, 2026 Filed Apr 17, 2026 20:15 UTC	ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040	GrantStock option (right to buy) · Derivative	100,000	$0.00 Strike: $1.68	$0.00	Disclosure SEC source: 0001193125-26-161557 · ownership.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-04-15 F1 · derivative.exercise_date: One-fourth of the shares subject to the option vest on February 25, 2027 and 1/48th vest monthly thereafter. Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:05 UTC	ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040	GrantStock option (right to buy) · Derivative	700,000	$0.00 Strike: $2.07	$0.00	Disclosure SEC source: 0001193125-26-093913 · ownership.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2036-03-02 F1 · derivative.exercise_date: One-fourth of the shares subject to the option vest on February 25, 2027 and 1/48th vest monthly thereafter. Read SEC document
September 17, 2025 Filed Sep 19, 2025 20:01 UTC	ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040	GrantStock option (right to buy) · Derivative	300,000	$0.00 Strike: $1.05	$0.00	Disclosure SEC source: 0001193125-25-209045 · ownership.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2035-09-16 F1 · derivative.exercise_date: One-third of the shares subject to the option vest on each of September 17, 2025, January 31, 2026 and June 30, 2026. Read SEC document
June 30, 2025 Filed Jul 2, 2025 20:32 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	GrantStock Option (Right to Buy) · Derivative	67,000	$0.00 Strike: $1.45	$0.00	Disclosure SEC source: 0000950170-25-093058 · ownership.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Voting Common Stock · 67,000 shares Expires 2035-06-30 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 30, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. Read SEC document
June 12, 2025 Filed Jun 16, 2025 23:33 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	27,372	$0.00 Strike: $9.43	$0.00	Disclosure SEC source: 0001127602-25-017602 · form4.xml · derivative · entry 2 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,372 Underlying: Common Stock · 27,372 shares Expires 2035-06-11 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 12, 2025, such that the total number of shares will be fully vested on June 12, 2026. Read SEC document
June 12, 2025 Filed Jun 16, 2025 23:33 UTC	Xencor Inc XNCR · Entity 4487	GrantCommon Stock	13,686	$0.00	$0.00	Disclosure SEC source: 0001127602-25-017602 · form4.xml · nonDerivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,672 F1 · shares: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. Read SEC document
January 21, 2025 Filed Jan 23, 2025 23:24 UTC	ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040	GrantStock Option (right to buy) · Derivative	40,400	$0.00 Strike: $1.65	$0.00	Disclosure SEC source: 0001415889-25-001973 · form4-01232025_110125.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,400 Underlying: Common Stock · 40,400 shares Expires 2035-01-20 F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on February 21, 2025. Read SEC document
September 23, 2024 Filed Sep 24, 2024 21:26 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	PurchaseVoting Common Stock	5,000	$5.29	$26,450.00	Disclosure SEC source: 0000950170-24-109133 · ownership.xml · nonDerivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Read SEC document
August 26, 2024 Filed Aug 27, 2024 22:57 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	PurchaseVoting Common Stock	5,000	$5.53	$27,650.00	Disclosure SEC source: 0000950170-24-101166 · ownership.xml · nonDerivative · entry 2 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Read SEC document
August 23, 2024 Filed Aug 27, 2024 22:57 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	PurchaseVoting Common Stock	5,000	$5.69	$28,450.00	Disclosure SEC source: 0000950170-24-101166 · ownership.xml · nonDerivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Read SEC document
June 13, 2024 Filed Jun 13, 2024 22:35 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	GrantStock Option (Right to Buy) · Derivative	800	$0.00 Strike: $1.38	$0.00	Disclosure SEC source: 0000950170-24-073209 · ownership.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock · 800 shares Expires 2034-06-12 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest in full on the earlier to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document
June 13, 2024 Filed Jun 17, 2024 20:25 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	11,971	$0.00 Strike: $21.31	$0.00	Disclosure SEC source: 0001127602-24-018839 · form4.xml · derivative · entry 2 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,971 Underlying: Common Stock · 11,971 shares Expires 2034-06-12 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 13, 2024, such that the total number of shares will be fully vested on June 13, 2025. Read SEC document
June 13, 2024 Filed Jun 17, 2024 20:25 UTC	Xencor Inc XNCR · Entity 4487	GrantCommon Stock	5,986	$0.00	$0.00	Disclosure SEC source: 0001127602-24-018839 · form4.xml · nonDerivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,986 F1 · shares: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. Read SEC document
June 12, 2024 Filed Jun 14, 2024 20:20 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	GrantStock Option (Right to Buy) · Derivative	47,500	$0.00 Strike: $8.88	$0.00	Disclosure SEC source: 0000950170-24-073694 · ownership.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Voting Common Stock · 47,500 shares Expires 2034-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. Read SEC document
February 19, 2024 Filed Feb 21, 2024 22:22 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	GrantStock Option (Right to Buy) · Derivative	2,000	$0.00 Strike: $11.32	$0.00	Disclosure SEC source: 0001209191-24-003698 · doc4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2034-02-18 F1 · derivative.exercise_date: The shares subject to the option will vest in substantially equal monthly installments over 12 months, commencing on February 19, 2024, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document
December 14, 2023 Filed Dec 18, 2023 23:01 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	PurchaseVoting Common Stock	5,000	$5.08	$25,400.00	Disclosure SEC source: 0000950170-23-071208 · ownership.xml · nonDerivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Read SEC document
September 15, 2023 Filed Sep 19, 2023 20:32 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	40,070	$0.00 Strike: $20.69	$0.00	Disclosure SEC source: 0001127602-23-024439 · form4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,070 Underlying: Common Stock · 40,070 shares Expires 2033-09-15 F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option vest and become exercisable on September 15, 2024, and the remaining shares vest in equal monthly installments over the subsequent 24 months. Read SEC document
June 22, 2023 Filed Jun 23, 2023 00:14 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.82	$0.00	Disclosure SEC source: 0001209191-23-039200 · doc4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest in full on the earlier to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document
June 13, 2023 Filed Jun 15, 2023 22:13 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	GrantStock Option (Right to Buy) · Derivative	36,524	$0.00 Strike: $2.66	$0.00	Disclosure SEC source: 0000899243-23-015639 · doc4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,524 Underlying: Voting Common Stock · 36,524 shares Expires 2033-06-12 F1 · derivative.exercise_date: 35,000 shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2024 and (ii) the next annual meeting of the Issuer's stockholders, with 1,524 shares subject to this option vesting and becoming exercisable in full on June 13, 2023, in each case subject to the Reporting Person's continued service at such time. Read SEC document
April 06, 2023 Filed Apr 10, 2023 14:39 UTC	TScan Therapeutics, Inc. TCRX · Entity 7255	GrantStock Option (Right to Buy) · Derivative	9,146	$0.00 Strike: $2.20	$0.00	Disclosure SEC source: 0000899243-23-010999 · doc4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,146 Underlying: Voting Common Stock · 9,146 shares Expires 2033-04-05 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in thirty-six equal monthly installments following April 6, 2023, subject to the Reporting Person's continued service at such time. Read SEC document
January 20, 2023 Filed Jan 24, 2023 21:10 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	GrantStock Option (Right to Buy) · Derivative	28,125	$0.00 Strike: $0.47	$0.00	Disclosure SEC source: 0001209191-23-004584 · doc4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,125 Underlying: Common Stock · 28,125 shares Expires 2033-01-19 F1 · derivative.exercise_date: The shares subject to the option will vest in substantially equal monthly installments over 12 months, commencing on January 20, 2023, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:43 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerStock Option (right to buy) · Derivative	50,000	$0.00 Strike: $31.54	$0.00	Disclosure SEC source: 0001209191-22-040274 · doc4.xml · derivative · entry 12 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2032-03-14 F9 · price: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F12 · derivative.exercise_date: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:43 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $16.73	$0.00	Disclosure SEC source: 0001209191-22-040274 · doc4.xml · derivative · entry 11 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2031-03-15 F9 · price: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F11 · derivative.exercise_date: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:43 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerStock Option (right to buy) · Derivative	49,000	$0.00 Strike: $12.15	$0.00	Disclosure SEC source: 0001209191-22-040274 · doc4.xml · derivative · entry 10 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,000 shares Expires 2030-08-12 F9 · price: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F10 · derivative.exercise_date: On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:43 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerStock Option (right to buy) · Derivative	167,091	$0.00 Strike: $13.31	$0.00	Disclosure SEC source: 0001209191-22-040274 · doc4.xml · derivative · entry 9 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 167,091 shares Expires 2030-02-25 F9 · price: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F8 · derivative.exercise_date: The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:43 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerStock Option (right to buy) · Derivative	4,999	$0.00 Strike: $78.40	$0.00	Disclosure SEC source: 0001209191-22-040274 · doc4.xml · derivative · entry 8 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,999 shares Expires 2029-03-04 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F7 · derivative.exercise_date: The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:43 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerStock Option (right to buy) · Derivative	4,508	$0.00 Strike: $94.40	$0.00	Disclosure SEC source: 0001209191-22-040274 · doc4.xml · derivative · entry 7 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,508 shares Expires 2028-03-06 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F6 · derivative.exercise_date: The option fully vested on January 1, 2022. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:43 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerStock Option (right to buy) · Derivative	1,749	$0.00 Strike: $58.00	$0.00	Disclosure SEC source: 0001209191-22-040274 · doc4.xml · derivative · entry 6 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,749 shares Expires 2027-03-06 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F5 · derivative.exercise_date: The option fully vested on January 1, 2021. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:43 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerStock Option (right to buy) · Derivative	11,399	$0.00 Strike: $72.80	$0.00	Disclosure SEC source: 0001209191-22-040274 · doc4.xml · derivative · entry 5 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,399 shares Expires 2026-09-30 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F4 · derivative.exercise_date: The option fully vested on September 30, 2019. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:43 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerStock Option (right to buy) · Derivative	2,061	$0.00 Strike: $263.20	$0.00	Disclosure SEC source: 0001209191-22-040274 · doc4.xml · derivative · entry 4 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,061 shares Expires 2016-03-08 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F3 · derivative.exercise_date: The option fully vested on January 1, 2020. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:43 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerStock Option (right to buy · Derivative	11,744	$0.00 Strike: $268.20	$0.00	Disclosure SEC source: 0001209191-22-040274 · doc4.xml · derivative · entry 3 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,744 shares Expires 2025-06-10 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F1 · derivative.exercise_date: The option fully vested on June 11, 2019. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:43 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerCommon Stock	5,000	$55.00	$275,000.00	Disclosure SEC source: 0001209191-22-040274 · doc4.xml · nonDerivative · entry 2 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:43 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerCommon Stock	10,000	$55.00	$550,000.00	Disclosure SEC source: 0001209191-22-040274 · doc4.xml · nonDerivative · entry 1 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document
June 17, 2022 Filed Jun 17, 2022 16:14 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	GrantStock Option (Right to Buy) · Derivative	12,250	$0.00 Strike: $12.15	$0.00	Disclosure SEC source: 0001209191-22-037845 · doc4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2030-08-12 F1 · date: On August 12, 2020, the reporting person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 12,250 shares. Read SEC document
June 09, 2022 Filed Jun 13, 2022 22:49 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $1.65	$0.00	Disclosure SEC source: 0001209191-22-036450 · doc4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest in full on the earlier to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document
March 14, 2022 Filed Mar 14, 2022 16:45 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $31.54	$0.00	Disclosure SEC source: 0001209191-22-018489 · doc4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-03-14 F1 · derivative.exercise_date: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
January 28, 2022 Filed Jan 28, 2022 18:34 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	GrantStock Option (Right to Buy) · Derivative	12,250	$0.00 Strike: $12.15	$0.00	Disclosure SEC source: 0001209191-22-005485 · doc4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2030-08-12 F1 · date: On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 12,250 shares. Read SEC document
November 01, 2021 Filed Nov 2, 2021 23:10 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $10.18	$0.00	Disclosure SEC source: 0001209191-21-062515 · doc4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-10-31 F1 · derivative.exercise_date: The shares subject to the option will vest in substantially equal monthly installments over three years, commencing on November 1, 2021, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document
March 15, 2021 Filed Mar 17, 2021 21:15 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $16.73	$0.00	Disclosure SEC source: 0001209191-21-021620 · doc4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-03-15 F1 · derivative.exercise_date: The option vests as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
August 18, 2020 Filed Aug 18, 2020 20:16 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	PurchaseCommon Stock	3,325	$12.25	$40,737.57	Disclosure SEC source: 0001209191-20-047352 · doc4.xml · nonDerivative · entry 2 Klencke Barbara · CIK 0001647647 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 5,000 F2 · price: Represents the weighted average purchase price. The lowest price at which shares were purchased was $12.22 and the highest price at which shares were purchased was $12.30. Read SEC document
August 18, 2020 Filed Aug 18, 2020 20:16 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	PurchaseCommon Stock	5,950	$12.22	$72,709.60	Disclosure SEC source: 0001209191-20-047352 · doc4.xml · nonDerivative · entry 1 Klencke Barbara · CIK 0001647647 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: Represents the weighted average purchase price. The lowest price at which shares were purchased was $12.21 and the highest price at which shares were purchased was $12.23. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares purchased at each separate price within the ranges set forth in footnotes 1 and 2 to this Form 4. Read SEC document
February 25, 2020 Filed Feb 27, 2020 16:15 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	GrantStock Option (right to buy) · Derivative	167,091	$0.00 Strike: $13.31	$0.00	Disclosure SEC source: 0001209191-20-013407 · doc4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,091 Underlying: Common Stock · 167,091 shares Expires 2030-02-25 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
August 23, 2019 Filed Aug 26, 2019 17:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	PurchaseCommon Stock	108,000	$0.44	$47,379.60	Disclosure SEC source: 0001209191-19-047421 · doc4.xml · nonDerivative · entry 3 Klencke Barbara · CIK 0001647647 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,000 F1 · price: Represents the weighted average purchase price. The lowest price at which shares were purchased was $0.4375 and the highest price at which shares were purchased was $0.4399. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares purchased at each separate price within the range set forth herein. Read SEC document
August 22, 2019 Filed Aug 26, 2019 17:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	PurchaseCommon Stock	54,000	$0.45	$24,294.60	Disclosure SEC source: 0001209191-19-047421 · doc4.xml · nonDerivative · entry 2 Klencke Barbara · CIK 0001647647 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Read SEC document
August 22, 2019 Filed Aug 26, 2019 17:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	PurchaseCommon Stock	67,000	$0.43	$28,964.10	Disclosure SEC source: 0001209191-19-047421 · doc4.xml · nonDerivative · entry 1 Klencke Barbara · CIK 0001647647 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 67,000 Read SEC document
March 04, 2019 Filed Mar 5, 2019 17:29 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	GrantStock Option (right to buy) · Derivative	200,000	$0.00 Strike: $1.96	$0.00	Disclosure SEC source: 0001209191-19-016742 · doc4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-03-04 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
March 06, 2018 Filed Mar 7, 2018 17:55 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	GrantStock Option (right to buy) · Derivative	180,360	$0.00 Strike: $2.36	$0.00	Disclosure SEC source: 0001209191-18-017781 · doc4.xml · derivative · entry 1 Klencke Barbara · CIK 0001647647 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,360 Underlying: Common Stock · 180,360 shares Expires 2028-03-06 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on January 1, 2019, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.